Nerandomilast
Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It is a phosphodiesterase 4 inhibitor. It is taken by mouth.
Side effects include diarrhea, decreased weight, decreased appetite, and nausea.
Nerandomilast was approved for medical use in the United States in October 2025.
Medical uses
Nerandomilast is indicated for the treatment of idiopathic pulmonary fibrosis and for the treatment of progressive pulmonary fibrosis.Idiopathic pulmonary fibrosis affects the tissue surrounding the air sacs, or alveoli, in the lungs. It develops when this lung tissue becomes thick and stiff. Over time, these changes can cause permanent lung scarring that makes it more difficult to breathe.
Progressive pulmonary fibrosis is a chronic disease characterized by gradual, irreversible scarring of the lungs, which can lead to progressive breathing difficulties. Progressive pulmonary fibrosis is an umbrella term that can describe progressive lung scarring in many interstitial lung diseases.
Side effects
Side effects include diarrhea, decreased weight, decreased appetite, and nausea.History
The efficacy of nerandomilast for the treatment of idiopathic pulmonary fibrosis was evaluated in two randomized, double-blind, placebo-controlled trials of adults with idiopathic pulmonary fibrosis.The efficacy of nerandomilast for the treatment of progressive pulmonary fibrosis was demonstrated in FIBRONEER-ILD, a randomized, double-blind, placebo-controlled study that enrolled 1,178 adults with progressive pulmonary fibrosis. Participants were randomly assigned 1:1:1 to receive twice daily administration of nerandomilast 9mg, nerandomilast 18mg, or placebo, for at least 52 weeks.
Society and culture
Legal status
Nerandomilast was approved for medical use in the United States in October 2025.The US Food and Drug Administration granted the application for nerandomilast an orphan drug designation for the idiopathic pulmonary fibrosis indication and breakthrough therapy designation for the progressive pulmonary fibrosis indication.
Names
Nerandomilast is the international nonproprietary name.Nerandomilast is sold under the brand name Jascayd.